Uncategorized

An Exclusive Interview with Dr. Francis Collins on 10 Years of Advancing NF1 Research through NTAP’s Francis S. Collins Scholars Program

November 21, 2024

In this exclusive interview, Dr. Francis S. Collins, renowned geneticist and former Director of the National Institutes of Health, reflects on the impact of the Francis Collins Scholars (FCS) Program for Neurofibromatosis Type 1 (NF1) […]

Read More

The Impact of Mentorship and Collaboration in NF1 Research: An Interview with Dr. Shruti Garg and Dr. Steven Rhodes

November 20, 2024

Over the past ten years, the Francis Collins Scholars (FCS) Program has had a transformative impact on the careers of early-career researchers in the field of neurofibromatosis type 1 (NF1) and related disorders. In interviews […]

Read More

A Decade Of Impact The Francis Collins Scholars Program Is Driving The Future Of Nf1 Research

November 20, 2024

Baltimore, MD – In 2014, the Francis S. Collins Scholars Program (FCS) in Neurofibromatosis Clinical and Translational Research was launched to transform the landscape of NF1 research by attracting top clinician-scientists into the field. Named […]

Read More

Selumetinib in Children with Inoperable Plexiform Neurofibromas

April 22, 2020

N Engl J Med 2020; 382:1430-1442 DOI: 10.1056/NEJMoa1912735 List of authors. Andrea M. Gross, M.D., Pamela L. Wolters, Ph.D., Eva Dombi, M.D., Andrea Baldwin, P.N.P., Patricia Whitcomb, R.N., Michael J. Fisher, M.D., Brian Weiss, M.D., […]

Read More

Selumetinib: The First Effective Treatment for Plexiform Neurofibromas

April 22, 2020

A young patient with NF1 who was treated at NCI gathers with her mother and members of NCI’s Pediatric Oncology Branch. Credit: National Institutes of Health Over 30 years of NCI-led and NCI-supported research culminated […]

Read More

Induced pluripotent stem cells have been generated for the first time from tumor cells in order to study therapies for tumors developed in patients with hereditary diseases with predisposition to cancer

February 13, 2019

Induced pluripotent stem cells have been generated for the first time from tumor cells in order to study therapies for tumors developed in patients with hereditary diseases with predisposition to cancer  The study focuses on […]

Read More

Data made available for Research Tools that Accelerate Development of Therapies for Neurofibromatosis Type 1 Plexiform Neurofibromas

October 22, 2018

For Release: October 2018 Development of therapies for human disease remains dependent on well-characterized and validated model systems.  Slow growing histologically benign tumors such as neurofibromas are challenging to grow in typical culture conditions.  As […]

Read More

Data made available for a 3D model of Neurofibromatosis Type 1 Plexiform Neurofibromas

October 22, 2018

For Release: October 2018 Development of therapies for human disease remains dependent on well-characterized and validated model systems for pre-clinical therapeutic testing. Most in vitro drug testing is performed on cells growing in two dimensions […]

Read More

Two New Clinician-Scientists Chosen for Neurofibromatosis Award, Research Support

July 13, 2018

Author: Cathy Gara. July 2018–The Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the Johns Hopkins University School of Medicine is proud to announce that Dr. Shruti Garg, of the University of Manchester, and Dr. Ina Ly, […]

Read More

Funding Available for Neurofibromatosis Research from the Department of Defense – Congressionally Directed Medical Research Programs

July 13, 2018

The FY18 Neurofibromatosis Research Program (NFRP) is accepting applications for research projects. Applications to the Fiscal Year 2018 (FY18) Neurofibromatosis Research Program (NFRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development […]

Read More